Barclays Downgrades Spark Therapeutics (ONCE) to Equalweight Following Acquisition

March 25, 2019 1:46 AM EDT
Get Alerts ONCE Hot Sheet
Price: $110.05 --0%

Rating Summary:
    5 Buy, 19 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 7 | Down: 15 | New: 24
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Barclays analyst Gena Wang downgraded Spark Therapeutics (NASDAQ: ONCE) from Overweight to Equalweight with a price target of $115.00 (from $74.00).

For an analyst ratings summary and ratings history on Spark Therapeutics click here. For more ratings news on Spark Therapeutics click here.

Shares of Spark Therapeutics closed at $113.00 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change, Downgrades

Related Entities

Barclays, Gena Wang